Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
Study sponsor: Lisata Therapeutics, Inc. · LSTA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-05-19Actual
Enrollment · participants33Actual
Source updated2024-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.